IL323792A - New treatment for SMA - Google Patents

New treatment for SMA

Info

Publication number
IL323792A
IL323792A IL323792A IL32379225A IL323792A IL 323792 A IL323792 A IL 323792A IL 323792 A IL323792 A IL 323792A IL 32379225 A IL32379225 A IL 32379225A IL 323792 A IL323792 A IL 323792A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
dimethylimidazo
diazaspiro
octan
pyridazin
Prior art date
Application number
IL323792A
Other languages
Hebrew (he)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60019743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL323792(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL323792A publication Critical patent/IL323792A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • External Artificial Organs (AREA)

Claims (18)

- 72 - Claims
1. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA) at 0.25 mg/kg for patients with a body weight of less than 20kg.
2. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6- yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to claim 1, in patient in need thereof, wherein the patient is a human.
3. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to claim 1 or 2, wherein 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6- yl)pyrido[1,2-a]pyrimidin-4-one is orally administered.
4. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to any one of claims 1 to 3, wherein the patient is a human, wherein 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one is being administered orally at 0.25mg/kg for patients with a body weight of less than 20kg.
5. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to any one of claims 1 to 4, wherein SMA is type II SMA.
6. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6- yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to any one of claims 1 to 5, wherein 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one is administered once a day.
7. A pharmaceutical composition for use in the treatment of SMA, at 0.25 mg per kilogram of body weight of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2- b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for patients with a body weight of less than 20kg, being administered, in particular orally administered once a day, wherein the pharmaceutical composition comprises 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof formulated as oral aqueous solution by dissolving 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof in a buffer system at pH of less than pH 4, in order to provide sufficiently high drug concentration, - 73 - e.g. citric buffer system, malate buffer system, maleate buffer system, or tartrate buffer system.
8. The pharmaceutical composition for use according to claim 7, wherein the buffer system is at pH 3.0 to 3.2.
9. The pharmaceutical composition for use according to claim 7, wherein the buffer system is tartrate buffer system.
10. The pharmaceutical composition for use according to any one of claims 7 to 9, wherein the pharmaceutical composition comprises 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof as a dry powder or granulation for constitution of an oral solution.
11. The pharmaceutical composition for use according to any one of claims 7 to 10, wherein a buffer system can be incorporated into dry formulation by the selection of organic acid and salts thereof as fine powders, e.g. tribasic sodium citrate and citric acid, disodium malate and malic acid, potassium sodium tartrate and tartaric acid, or disodium tartrate and tartaric acid.
12. The pharmaceutical composition for use according to any one of claims 7 to 10, wherein the pharmaceutical composition comprises 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof, a diluent, such as sorbitol, isomalt, or mannitol, and combinations thereof, which ensure fast dissolution of the powder blend during constitution of the oral solution and optionally, filler can be added to be granulated by dry compaction in order to improve the flowability and to ensure robust uniformity.
13. The pharmaceutical composition for use according to any one of claims 7 to 12, wherein the pharmaceutical composition comprises:  7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof; and  tartaric acid.
14. The pharmaceutical composition for use according to any one of claims 7 to 13, wherein the pharmaceutical composition comprises:  7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof; - 74 -  tartaric acid; and  mannitol or a mixture of mannitol and isomalt.
15. The pharmaceutical composition for use according to any one of claims 7 to 14, wherein the pharmaceutical composition comprises:  7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6- yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof; and  mannitol or a mixture of mannitol and isomalt.
16. The pharmaceutical composition for use according to any one of claims 7 to 15, wherein the pharmaceutical composition comprises:  7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6- yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof;  tartaric acid;  ascorbic acid; and  disodium edetate.
17. The pharmaceutical composition for use according to any one of claims 7 to 16, wherein the pharmaceutical composition comprises:  7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof;  tartaric acid;  mannitol or a mixture of mannitol and isomalt;  ascorbic acid; and  disodium edetate.
18. The pharmaceutical composition for use according to any one of claims 7 to 12, wherein the pharmaceutical composition comprises: - 75 -  1 to 10 %wt of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof;  5 to 15 %wt of a buffer system, particularly a buffer system selected from citrate, malate, maleate or tartrate, more particularly malate or tartrate, most particularly tartrate; or alternatively the corresponding acid of a buffer system alone as acidifier, particularly tartaric acid;  40 to 70 %wt of a diluent, particularly mannitol or a mixture of mannitol and isomalt, more particularly mannitol;  1 to 4 %wt of an antioxidant, particularly ascorbic acid;  0.5 to 2 %wt of a stabilizer, particularly disodium edetate;  0.5 to 2 %w of a lubricant, particularly PEG6000;  0 to 3 %wt of a sweetener, particularly sucralose or sodium saccharin, most particularly sucralose; and  0 to 20 %wt of a flavor, particularly strawberry flavor or vanilla flavor; wherein the total amount of ingredients does not exceed 100 %wt.
IL323792A 2017-10-03 2018-10-01 New treatment for SMA IL323792A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17194520 2017-10-03
PCT/EP2018/076577 WO2019068604A1 (en) 2017-10-03 2018-10-01 New treatment of sma

Publications (1)

Publication Number Publication Date
IL323792A true IL323792A (en) 2025-12-01

Family

ID=60019743

Family Applications (2)

Application Number Title Priority Date Filing Date
IL273543A IL273543B2 (en) 2017-10-03 2018-10-01 New treatment of sma
IL323792A IL323792A (en) 2017-10-03 2018-10-01 New treatment for SMA

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL273543A IL273543B2 (en) 2017-10-03 2018-10-01 New treatment of sma

Country Status (12)

Country Link
US (2) US11534444B2 (en)
EP (2) EP3691647B1 (en)
JP (3) JP7423515B2 (en)
KR (1) KR102761837B1 (en)
CN (2) CN111182900A (en)
AU (2) AU2018344402B2 (en)
CA (1) CA3078137A1 (en)
ES (1) ES3072590T3 (en)
IL (2) IL273543B2 (en)
MX (2) MX2020003416A (en)
TW (1) TWI870340B (en)
WO (1) WO2019068604A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3072590T3 (en) * 2017-10-03 2026-07-02 Hoffmann La Roche New treatment of sma
WO2020249577A1 (en) * 2019-06-12 2020-12-17 F. Hoffmann-La Roche Ag New treatment of sma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
AU2015261046C1 (en) 2014-05-15 2019-07-25 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
MX375925B (en) * 2014-06-25 2025-03-07 Hoffmann La Roche IMIDAZO[1,2-A]PYRAZIN-1-YL-BENZAMIDE COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY.
AR106652A1 (en) * 2015-11-12 2018-02-07 Hoffmann La Roche COMPOUNDS TO TREAT AMIOTROPHIC LATERAL SCLEROSIS
AU2016353961B2 (en) 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
ES3072590T3 (en) * 2017-10-03 2026-07-02 Hoffmann La Roche New treatment of sma

Also Published As

Publication number Publication date
EP4755451A3 (en) 2026-08-19
IL273543B1 (en) 2025-12-01
US11534444B2 (en) 2022-12-27
KR20200065025A (en) 2020-06-08
JP2020536090A (en) 2020-12-10
JP2024041949A (en) 2024-03-27
EP3691647C0 (en) 2026-05-27
AU2018344402B2 (en) 2024-08-29
EP3691647A1 (en) 2020-08-12
IL273543A (en) 2020-05-31
EP4755451A2 (en) 2026-06-10
JP7423515B2 (en) 2024-01-29
EP3691647B1 (en) 2026-05-27
MX2020003416A (en) 2020-07-20
US20200375993A1 (en) 2020-12-03
TWI870340B (en) 2025-01-21
AU2018344402A1 (en) 2020-04-09
WO2019068604A1 (en) 2019-04-11
JP2024102152A (en) 2024-07-30
IL273543B2 (en) 2026-04-01
MX2023004924A (en) 2023-05-17
TW201924684A (en) 2019-07-01
ES3072590T3 (en) 2026-07-02
AU2024266812A1 (en) 2024-12-12
KR102761837B1 (en) 2025-02-05
CN117919251A (en) 2024-04-26
CA3078137A1 (en) 2019-04-11
US12350273B2 (en) 2025-07-08
CN111182900A (en) 2020-05-19
US20230338382A1 (en) 2023-10-26
JP7481593B2 (en) 2024-05-10

Similar Documents

Publication Publication Date Title
US12396947B2 (en) Methotrexate composition
EP1200091B1 (en) Pharmaceutical composition comprising tadalafil
ES2391912T3 (en) Valganciclovir powder formulation
EP3003384B1 (en) Oral solution comprising atomoxetine hydrochloride
WO2016159897A1 (en) Potassium citrate suspension
WO2011014248A1 (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
KR20150002453A (en) Chewable tablet formulation comprising tadalafil or a pharmaceutically acceptable salt thereof
WO2011136751A2 (en) Water soluble pharmaceutical composition
JP2022536669A5 (en)
IL273543B1 (en) New treatment for SMA
EP2566448B1 (en) Efervescent formulations comprising cefdinir
KR101634382B1 (en) Oral liquid formulation of tadalafil
EP2528593A2 (en) Effervescent formulations comprising cefprozil as active agent
EP1651191A2 (en) Effervescent pharmaceutical compositions containing vitamin d, calcium and phospate and their therapeutic use
WO2006129160A2 (en) Stable aqueous oral solution of risperidone
WO2013109230A1 (en) Pharmaceutical compositions comprising tadalafil
RU2011140785A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF TYPE 2 DIABETES
EP3678498B1 (en) Composition for calcium supplementation
EP3678497B1 (en) Composition for calcium supplementation
KR101638452B1 (en) Sildenafil-Bentonite-AEA Nanohybrid, Pharmaceutical Composition Containing the Same and Method for Preparing the Same
ES2406757T3 (en) Orodispersible tablet containing a sildenafil salt
WO2014027973A1 (en) Paliperidone oral solution
US20230082870A1 (en) Composition for calcium supplementation
KR20160012921A (en) Oral fast dissolving formulation containing blonanserin
CN104352461A (en) Oral pharmaceutical preparation of tadalafil